High Interleukin 27 Production is Associated with Early Clinical Stage and Localized Disease in Patients with Melanoma

Abstract

SummaryBackgroundThe immune response in patients with melanoma is an important focus of research due to the tumor’s resistance and immunotherapy possibilities. IL-27 is one of the cytokines with antitumor properties. The role of IL-27 in the pathogenesis of melanoma is still unclear. The aim of this study was to examine the association between serum IL-27 levels and the clinical parameters of melanoma patients.MethodsThe IL-27 concentration was determined by com mercial ELISA in serum samples from melanoma patients (n=72) and healthy control subjects (n=44). Patients were classified according to AJCC clinical stage, TNM stage, the length of progression-free interval (PFI) and the extent of the disease (localized or widespread).ResultsAverage IL-27 values were increased in patients with early stages of melanoma compared to patients with terminal stages and control values. The highest IL-27 concentration was found in stage IIa. Patients in stages III and IV had significantly lower values of IL-27 compared to control. Patients with localized melanoma and shorter PFI had insignificantly increased IL-27 levels compared to patients with widespread disease and longer PFI. Patients with metastatic disease and stage TNM4 had significantly lower average IL-27 values compared to control. Patients with high production of IL-27 (>1000 pg/mL) were most numerous in IIa AJCC stage, with initial tumor size TNM2 and in the group of patients with localized disease.ConclusionsHigh levels of IL-27 in patients with melanoma are associated with the initial stages and lo calized disease.

The Analysis of Inflammation-Related Proteins in a Cargo of Exosomes Derived from the Serum of Uveal Melanoma Patients Reveals Potential Biomarkers of Disease Progression

“…Similarly to our studies the serum level of IL-27 did not correspond with metastatic disease as it was shown in the example of melanoma. However, there is a lack of data about their role in exosomal cargo [47][48][49], but their high expression, in general, is one of the markers of response to immunotherapy. Although we did not detect the IL-6 in the UM patient-derived exosomes, we detected its soluble receptors, which may alter the sensitivity to IL-6 stimulation of cells exposed to these exosomes.…”

Cutaneous melanoma dissemination is dependent on the malignant cell properties and factors of intercellular crosstalk in the cancer microenvironment (Review)

“…On the other hand, it is also known as a potent inducer of the production of IL6 and IL8 in endothelial cells. It is highly expressed in the initial stages of CMM ( 89 ), stimulating the CMM growth and tumour vascularisation.…”